Edgewood Management’s Ginkgo Bioworks DNA Stock Holding History

Edgewood Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$496K	Hold	50,000	–	–	0.01%	75
2026 Q1	$307K	Hold	50,000	–	–	﹤0.01%	85
2025 Q4	$416K	Buy	+50,000	New	+$538K	﹤0.01%	80
2024 Q3	–	Sell	-6,250	Closed	-$83.6K	–	79
2024 Q2	$83.6K	Hold	6,250	–	–	﹤0.01%	80
2024 Q1	$290K	Hold	6,250	–	–	﹤0.01%	73
2023 Q4	$423K	Hold	6,250	–	–	﹤0.01%	67
2023 Q3	$453K	Hold	6,250	–	–	﹤0.01%	66
2023 Q2	$465K	Hold	6,250	–	–	﹤0.01%	68
2023 Q1	$333K	Buy	6,250 +1,250	+25%	+$79.2K	﹤0.01%	71
2022 Q4	$338K	Buy	5,000 +1,250	+33%	+$115K	﹤0.01%	72
2022 Q3	$468K	Buy	3,750 +1,250	+50%	+$149K	﹤0.01%	66
2022 Q2	$238K	Buy	+2,500	New	+$305K	﹤0.01%	73
2022 Q1	–	Sell	-250	Closed	-$83K	–	85
2021 Q4	$83K	Hold	250	–	–	﹤0.01%	84
2021 Q3	$116K	Buy	+250	New	+$122K	﹤0.01%	82

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Edgewood Management's DNA Position: Q2 2026 in Review

Edgewood Management held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 50,000 shares worth $496K. The position accounts for 0.01% of the portfolio, ranked #75.

Edgewood Management first reported a position in DNA in Q3 2021 and has held it in 14 quarters since. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Edgewood Management held 50,000 shares of Ginkgo Bioworks worth $496K as of Q2 2026.
Edgewood Management left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up 0.01% of Edgewood Management's portfolio in Q2 2026, its #75 holding.
Edgewood Management first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 14 quarters since.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Edgewood Management's 13F filing for Q2 2026, filed 13 Aug 2026.